Chabiotech Co.,Ltd. (085660.KQ)
KRW 15280.0
(-2.98%)
KRW 15280.0
(-2.98%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1069.23 Billion KRW | 11.95% |
| 2022 | 955.07 Billion KRW | 28.71% |
| 2021 | 742.01 Billion KRW | 9.63% |
| 2020 | 676.83 Billion KRW | 36.29% |
| 2019 | 496.62 Billion KRW | 25.0% |
| 2018 | 397.28 Billion KRW | 3.15% |
| 2017 | 385.15 Billion KRW | -1.26% |
| 2016 | 390.06 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1209.49 Billion KRW | 9.2% |
| 2024 Q1 | 1107.56 Billion KRW | 3.59% |
| 2023 Q1 | 1040.63 Billion KRW | 8.96% |
| 2023 FY | 1069.23 Billion KRW | 11.95% |
| 2023 Q4 | 1069.23 Billion KRW | -0.78% |
| 2023 Q3 | 1077.59 Billion KRW | 2.91% |
| 2023 Q2 | 1047.13 Billion KRW | 0.62% |
| 2022 Q2 | 918.71 Billion KRW | 19.47% |
| 2022 Q4 | 955.07 Billion KRW | -6.81% |
| 2022 Q3 | 1024.83 Billion KRW | 11.55% |
| 2022 FY | 955.07 Billion KRW | 28.71% |
| 2022 Q1 | 768.98 Billion KRW | 3.63% |
| 2021 Q3 | 670.76 Billion KRW | 0.0% |
| 2021 Q4 | 742.01 Billion KRW | 10.62% |
| 2021 FY | 742.01 Billion KRW | 9.63% |
| 2020 FY | 676.83 Billion KRW | 36.29% |
| 2019 FY | 496.62 Billion KRW | 25.0% |
| 2018 FY | 397.28 Billion KRW | 3.15% |
| 2017 FY | 385.15 Billion KRW | -1.26% |
| 2016 FY | 390.06 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | -530.91% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -56763.324% |
| BINEX Co., Ltd. | 75.68 Billion KRW | -1312.726% |
| Bioneer Corporation | 80.61 Billion KRW | -1226.424% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -5249.729% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | -687.737% |
| CrystalGenomics, Inc. | 97.82 Billion USD | -993.037% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -1353.606% |
| Medy-Tox Inc. | 137.14 Billion KRW | -679.665% |
| Peptron, Inc. | 16.36 Billion KRW | -6432.096% |
| Amicogen, Inc. | 248.12 Billion KRW | -330.928% |
| Genexine, Inc. | 79.68 Billion KRW | -1241.863% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -3552.264% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -2490.147% |
| ALTEOGEN Inc. | 108.25 Billion KRW | -887.672% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -1362.972% |
| SillaJen, Inc. | 19.4 Billion KRW | -5411.261% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | -497.035% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -1937.064% |
| Genomictree Inc. | 7.81 Billion KRW | -13586.639% |
| MedPacto, Inc. | 9.56 Billion KRW | -11077.791% |
| D&D Pharmatech | 23.98 Billion KRW | -4357.816% |
| EASY BIO,Inc. | 105.86 Billion KRW | -909.964% |
| GI Innovation, Inc. | 9.63 Billion KRW | -10996.037% |